Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.34B), while Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7.4× Invesco DB Commodity Index Tracking Fund's market cap, and Invesco DB Commodity Index Tracking Fund is more actively traded (569,977 versus 1,242,136). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Invesco DB Commodity Index Tracking Fund for 61 Days on average.
| CRL | DBC | |
|---|---|---|
Market Cap | $14.34B | $1.93B |
Volume | 1,242,136 | 569,977 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $33.68 |
52-Week Low | $149.93 | $22.07 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $17.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 2.28% on the day, but maintains a bullish technical outlook with strong analyst support. The stock has consistently beaten earnings expectations in recent quarters, though profitability metrics show challenges with negative net income margins and ROE. Recent investor day presentations highlighted a refreshed growth strategy targeting 5-7% organic revenue growth and $300 million in cost savings by 2030, providing fundamental catalysts.
While CRL faces profitability headwinds and premium valuation multiples, strong analyst consensus (73% buy ratings) and a $305.50 price target suggest upside potential. Key risks include execution on margin improvement targets and ongoing cost volatility in non-human primate services. The combination of technical strength, strategic initiatives, and Wall Street support creates a favorable risk-reward profile for growth-oriented investors.
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
